Terns Pharmaceuticals, Inc.
TERN
Classifica tra le azioni
#3571
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Prezzo delle azioni
$52.95
Ultima sincronizzazione: 2026-05-15
Capitalizzazione di mercato
$4.77B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
529.61%
Paese
US
Scambia Terns Pharmaceuticals, Inc. (TERN)
Categoria
Healthcare
Rapporto P/B per Terns Pharmaceuticals, Inc. (TERN)
Rapporto P/B al October 2026 TTM: 4.90
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Terns Pharmaceuticals, Inc., il rapporto P/B attuale (TTM) è 4.90. Alla fine del 2023, era pari a 1.81.
Storico del rapporto P/B per Terns Pharmaceuticals, Inc. da 2018 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 4.90 | 285.92% |
| 2024 | 1.27 | -29.68% |
| 2023 | 1.81 | 36.73% |
| 2022 | 1.32 | 18.84% |
| 2021 | 1.11 | -83.46% |
| 2020 | 6.74 | -93.86% |
| 2019 | 109.70 | 1,697.47% |
| 2018 | 6.10 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 6.251 | 27.54% |
US
|
|
| 13.2547 | 170.44% |
US
|
|
| 4.208 | -14.14% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 26.14% |
NL
|
